Tela Bio

Yahoo Finance • 20 days ago

TELA outlines at least 8% 2026 revenue growth while guiding Q2 revenue to about $20.0M

Earnings Call Insights: TELA Bio (TELA) Q1 2026 MANAGEMENT VIEW * "Last quarter, we laid out a framework detailing the decisive steps we have taken to reset our commercial strategy, and Q1 results show early proof points that our strat... Full story

Yahoo Finance • 20 days ago

TELA Bio Reports First Quarter 2026 Financial Results

MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the firs... Full story

Yahoo Finance • 25 days ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio, Inc. MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced... Full story

Yahoo Finance • 2 months ago

Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation

Earnings Call Insights: TELA Bio, Inc. (TELA) Q4 2025 MANAGEMENT VIEW * Antony Koblish, Co-founder, CEO & Director, highlighted that 2025, particularly the third and fourth quarters, was a period of "meaningful strategic change across... Full story

Yahoo Finance • 2 months ago

TELA Bio (TELA) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, March 24, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Antony KoblishPresident — Jeffrey BlizardChief Financial Officer — Roberto E. CucaChief Commercial Officer — Jim Ha... Full story

Yahoo Finance • 5 months ago

Becton, Dickinson accused of hindering competition in hernia mesh market

[Meshes For Hernia] PhotoGraphyKM * Tela Bio (TELA [https://seekingalpha.com/symbol/TELA]) has filed a lawsuit accusing Becton, Dickinson (BDX [https://seekingalpha.com/symbol/BDX]) of stymying competition in the US market for surgical... Full story

Yahoo Finance • 6 months ago

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will part... Full story

Yahoo Finance • 7 months ago

Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet

Earnings Call Insights: TELA Bio (TELA) Q3 2025 MANAGEMENT VIEW * Antony Koblish, CEO, emphasized the company's continued execution on expanding its commercial footprint, improving operating discipline, and strengthening its patient-ce... Full story

Yahoo Finance • 7 months ago

TELA Bio prices $13M registered direct offering of common stock, pre-funded warrants

* TELA Bio (TELA [https://seekingalpha.com/symbol/TELA]) priced [https://seekingalpha.com/pr/20307445-tela-bio-announces-pricing-of-13_0-million-underwritten-registered-direct-offering-of-common] an underwritten registered direct offerin... Full story

Yahoo Finance • 7 months ago

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten r... Full story

Yahoo Finance • 7 months ago

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the thi... Full story

Yahoo Finance • 8 months ago

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointme... Full story

Yahoo Finance • 10 months ago

TELA Bio Reports Second Quarter 2025 Financial Results

MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the sec... Full story

Yahoo Finance • 10 months ago

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will part... Full story

Yahoo Finance • 10 months ago

TELA Bio to Announce Second Quarter 2025 Financial Results

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Comp... Full story

Yahoo Finance • 11 months ago

Deutsche Bank initiates coverage on Telekom Austria with “hold” rating

Investing.com -- Deutsche Bank has initiated coverage on Telekom Austria (VIE:TELA) with a "hold" rating and a price target of €11, citing the group’s steady performance across challenging markets and conservative balance sheet. Shares of... Full story

Yahoo Finance • 12 months ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcome... Full story

Yahoo Finance • 12 months ago

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the European launch of Ovi... Full story

Yahoo Finance • 12 months ago

TELA Bio Appoints Jeffrey Blizard as President

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey B... Full story

Yahoo Finance • last year

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will parti... Full story